Compare TechnipFMC plc Ordinary Share (FTI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TechnipFMC plc Ordinary Share vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? TechnipFMC plc Ordinary Share trades at $69.36 (market cap $27.73B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: TechnipFMC plc Ordinary Share is far larger — about 28.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and TechnipFMC plc Ordinary Share pays a 0.28% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold TechnipFMC plc Ordinary Share for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FTI | MRVI | |
|---|---|---|
Market Cap | $27.73B | $972.90M |
Volume | 2,487,618 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $80.08 | $9.00 |
52-Week Low | $35.57 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $27.98B | $1.08B |
Dividend Yield | 0.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTI trades at $70.72, up 1.39% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 36.04% ROE and 11.28% net margin. Recent Petrobras contract wins and strategic hires strengthen its subsea and consulting capabilities. Analyst consensus remains bullish with a $80.50 price target representing 14% upside potential.
FTI presents a compelling growth story with consistent earnings outperformance and strategic expansion, though technical indicators suggest near-term consolidation. The primary risk involves execution of recent contracts and maintaining profitability amid rising expenses. With zero sell ratings and institutional accumulation, the stock offers upside potential for investors comfortable with energy sector volatility.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TechnipFMC plc Ordinary Share
TechnipFMC is an energy technology company providing subsea systems, surface technologies, and related services across the life of oil and gas fields. Its offerings include equipment, controls, installation support, and digital tools for offshore and onshore projects.
Read more on FTI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
